# Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors

> **NCT01694472** · PHASE1 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Malignant Solid Tumors

## Interventions

- **BIOLOGICAL:** MAGE-A4 TCR Gene-Modified T Cells

## Key facts

- **NCT ID:** NCT01694472
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-07
- **Primary completion:** 2016-11
- **Final completion:** 2016-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2015-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01694472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01694472, "Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01694472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*